BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 29517409)

  • 1. Genetic predictors of efficacy and toxicity of iguratimod in patients with rheumatoid arthritis.
    Xiao W; Guo JP; Li C; Ye H; Wei W; Zou Y; Dai L; Li Z; Zhang M; Li X; Cai X; Zhao J; Wang Y; Tao Y; Liu D; Li Y; Wu M; Sun E; Wu L; Luo L; Mu R; Li Z
    Pharmacogenomics; 2018 Apr; 19(5):383-392. PubMed ID: 29517409
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of iguratimod
    Nozaki Y; Inoue A; Kinoshita K; Funauchi M; Matsumura I
    Mod Rheumatol; 2020 Mar; 30(2):249-258. PubMed ID: 30676812
    [No Abstract]   [Full Text] [Related]  

  • 3. Iguratimod, a synthetic disease modifying anti-rheumatic drug inhibiting the activation of NF-κB and production of RANKL: Its efficacy, radiographic changes, safety and predictors over two years' treatment for Japanese rheumatoid arthritis patients.
    Ishikawa K; Ishikawa J
    Mod Rheumatol; 2019 May; 29(3):418-429. PubMed ID: 29798702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [DMARDs (Focusing on iguratimod)].
    Ito S
    Nihon Rinsho; 2016 Jun; 74(6):948-54. PubMed ID: 27311184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The three-year efficacy of iguratimod in clinical daily practice in patients with rheumatoid arthritis.
    Suto T; Yonemoto Y; Okamura K; Sakane H; Takeuchi K; Tamura Y; Kaneko T; Ayabe K; Chikuda H
    Mod Rheumatol; 2019 Sep; 29(5):775-781. PubMed ID: 30092680
    [No Abstract]   [Full Text] [Related]  

  • 6. Iguratimod for the treatment of rheumatoid arthritis in Japan.
    Tanaka K; Yamaguchi T; Hara M
    Expert Rev Clin Immunol; 2015 May; 11(5):565-73. PubMed ID: 25797025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The add-on effectiveness and safety of iguratimod in patients with rheumatoid arthritis who showed an inadequate response to tocilizumab.
    Ebina K; Miyama A; Tsuboi H; Kaneshiro S; Nishikawa M; Owaki H; Tsuji S; Hirao M; Etani Y; Goshima A; Hashimoto J; Yoshikawa H
    Mod Rheumatol; 2019 Jul; 29(4):581-588. PubMed ID: 29882440
    [No Abstract]   [Full Text] [Related]  

  • 8. Effectiveness of iguratimod as monotherapy or combined therapy in patients with rheumatoid arthritis: a systematic review and meta-analysis of RCTs.
    Hu CJ; Zhang L; Zhou S; Jiang N; Zhao JL; Wang Q; Tian XP; Zeng XF
    J Orthop Surg Res; 2021 Jul; 16(1):457. PubMed ID: 34271950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis.
    Okamura K; Yonemoto Y; Okura C; Kobayashi T; Takagishi K
    Mod Rheumatol; 2015 Mar; 25(2):235-40. PubMed ID: 25065917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative efficacy and safety of iguratimod monotherapy for the treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis.
    Shrestha S; Zhao J; Yang C; Zhang J
    Clin Rheumatol; 2020 Jul; 39(7):2139-2150. PubMed ID: 32076916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and effectiveness of 24-week treatment with iguratimod, a new oral disease-modifying antirheumatic drug, for patients with rheumatoid arthritis: interim analysis of a post-marketing surveillance study of 2679 patients in Japan.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2017 Sep; 27(5):755-765. PubMed ID: 27919207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular mechanisms and clinical application of Iguratimod: A review.
    Jiang H; Gao H; Wang Q; Wang M; Wu B
    Biomed Pharmacother; 2020 Feb; 122():109704. PubMed ID: 31918275
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and effectiveness of iguratimod in patients with rheumatoid arthritis: Final report of a 52-week, multicenter postmarketing surveillance study.
    Mimori T; Harigai M; Atsumi T; Fujii T; Kuwana M; Matsuno H; Momohara S; Takei S; Tamura N; Takasaki Y; Yamamoto K; Ikeuchi S; Kushimoto S; Koike T
    Mod Rheumatol; 2019 Mar; 29(2):314-323. PubMed ID: 29611761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of add-on iguratimod in patients with rheumatoid arthritis who inadequately respond to either tocilizumab or tumor necrosis factor alpha inhibitors.
    Hattori K; Hirano Y; Kanayama Y; Hattori Y; Kato T; Takahashi N; Ishiguro N; Kojima T
    Mod Rheumatol; 2021 Jan; 31(1):80-87. PubMed ID: 32148143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical effectiveness of iguratimod based on real-world data of patients with rheumatoid arthritis.
    Mizutani S; Kodera H; Sato Y; Nanki T; Yoshida S; Yasuoka H
    Clin Rheumatol; 2021 Jan; 40(1):123-132. PubMed ID: 32506311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Add-on iguratimod as a therapeutic strategy to achieve remission in patients with rheumatoid arthritis inadequately responding to biological DMARDs: A retrospective study.
    Yoshikawa A; Yoshida S; Kimura Y; Tokai N; Fujiki Y; Kotani T; Matsumura Y; Takeuchi T; Makino S
    Mod Rheumatol; 2018 Mar; 28(2):227-234. PubMed ID: 28644744
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of combination therapy of iguratimod with methotrexate for patients with active rheumatoid arthritis with an inadequate response to methotrexate: an open-label extension of a randomized, double-blind, placebo-controlled trial.
    Hara M; Ishiguro N; Katayama K; Kondo M; Sumida T; Mimori T; Soen S; Nagai K; Yamaguchi T; Yamamoto K;
    Mod Rheumatol; 2014 May; 24(3):410-8. PubMed ID: 24252050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-allodynic action of the disease-modifying anti-rheumatic drug iguratimod in a rat model of neuropathic pain.
    Morimoto K; Miura A; Tanaka K
    Inflamm Res; 2017 Oct; 66(10):855-862. PubMed ID: 28612120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The addition of iguratimod can reduce methotrexate dose in rheumatoid arthritis with clinical remission.
    Yoshikawa A; Kotani T; Matsuda S; Hata K; Matsumura Y; Takeuchi T
    Mod Rheumatol; 2022 Jan; 32(1):68-73. PubMed ID: 33627038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iguratimod dose dependently inhibits the expression of citrullinated proteins and peptidylarginine deiminases 2 and 4 in neutrophils from rheumatoid arthritis patients.
    Li B; Li P; Bi L
    Clin Rheumatol; 2020 Mar; 39(3):899-907. PubMed ID: 31758423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.